|
|
||||||||
Eur J Cardiothorac Surg 1999;15:769-773
© 1999 Elsevier Science NL
Department of Thoracic Surgery, U.Z. Gasthuisberg, Catholic University of Leuven, Herestraat 49, 3000 Leuven, Belgium
Received 26 October 1998; received in revised form 8 March 1999; accepted 23 March 1999.
Corresponding author. Tel.: +32-16-346820; fax: +32-16-346821
e-mail: ermelinde.vaes{at}uz.kuleuven.ac.be
| Abstract |
|---|
|
|
|---|
Key Words: Adenocarcinoma pathology Lymphatic metastasis Lymph node excision Esophageal neoplasms Lymph node pathology
| 1. Introduction |
|---|
|
|
|---|
The long-term survival after resection remains poor because of the often advanced stage at the time of diagnosis. Undoubtedly one of the reasons is the high rate of lymph node metastasis at the time of diagnosis, in some reports reaching 80% [5]. Besides TNM stage grouping, lymph node metastasis seems the most important factor in predicting survival [6]. Lymph node metastasis in squamous cell carcinoma has been studied extensively [7]. On the contrary, little is known about the lymphogenic spread in adenocarcinoma of the distal esophagus and the gastro-esophageal junction.
The aim of this study is to analyze the pattern of lymph node metastasis of patients with adenocarcinoma of the distal esophagus and the gastro-esophageal junction and to study the behavior of lymphatic spread in these two groups.
| 2. Materials and methods |
|---|
|
|
|---|
From these 106 patients with a T3 (UICC classification, 4th edition) adenocarcinoma of the esophagus and proximal stomach, with nodal involvement we selected a subgroup of 37 patients. Those 37 patients all had an adenocarcinoma of the distal third of the esophagus (dist 1/3, n=17) or gastro-esophageal junction (GEJ, n=20) which all underwent a radical resection and a three-field lymphadenectomy (abdominal, thoracic and bilateral cervical dissection). While no strict definition of carcinoma of the gastro-esophageal junction exists, we considered all tumors with the core of the tumor located on the Z-line or within an area of 5 cm orally or aborally from the anatomic junction between the esophageal and the gastric wall. Three-field lymphadenectomy was considered representative when more then 25 nodes were recovered. The reasons for not performing three-field lymphadenectomy were diverse: advanced age (40/106 patients>70 years old), co-morbidity, peroperative instability or R2 situation (macroscopically incomplete resection). Patients who received induction chemo- or radiotherapy were excluded from this series. In all 37 patients clinical staging of the cervical region was negative for lymph node involvement.
In all 37 patients subtotal esophagectomy was performed through a thoracophrenolaparotomy using tubulated stomach for the reconstruction after resecting the complete lesser curvature. A cervical esophago-gastrostomy was performed to restore continuity. In the abdominal compartment all lymphatic tissue localized in the left upper quadrant is removed from the esophageal hiatus down to the celiac axis and the mesenteric artery. By incising the peritoneum at the dorsal side of the spleen, lymphatic tissue at the splenic hilum, the splenic artery and the retropancreatic area is removed. Dissection is continued along the common hepatic artery in the hepato-duodenal ligament. In the chest, a so-called posterior mediastinectomy is performed with clearance of all lymphatic tissue including the thoracic duct, subcarinal lymph nodes, aorto-pulmonary window and main stem bronchi lymph nodes. The cervical lymphadenectomy includes bilateral dissection of lymph nodes lateral of the carotid vessels, the internal jugular and supraclavicular lymph nodes, the lymph nodes along the recurrent nerves and nodes from the upper mediastinum.
Charting of the lymph nodes was done, using a database, counting the number of resected and malignant nodes in the specimen and in lymph nodes separately taken and identified during surgery.
| 3. Results |
|---|
|
|
|---|
The total amount of nodes excised was 2240 (mean 59.5±16.5, range 2691). Mean number of resected lymph nodes per region was: 18.6 for the cervical region, 19.8 for the thoracic region and 24.2 for the abdominal region. The overall ratio of positive nodes was 12.7% (129/1020) for the dist 1/3 and 15.9% (194/1220) for the GEJ (Table 1).
|
Table 2 shows the number of patients with positive nodes in different locations. 20% (n=4, one bilateral, two right sided, one left sided) of patients with a GEJ tumor had positive cervical lymph nodes, the percentage being 35.3% (n=6, one bilateral, four right sided, one left sided) for distal third carcinomas. Abdominal lymph nodes were positive in all patients of the GEJ group and in 70.6% of patients with dist 1/3 tumors. Thoracic lymph nodes were involved in up to 40% of patients with a GEJ tumor and 70.6% in distal third tumors.
|
| 4. Discussion |
|---|
|
|
|---|
In all patients lymph node involvement was unforeseen, clinical staging with the ultrasound of the neck, computed tomography of neck and chest and endoscopic ultrasonography all being negative. Surprisingly three of the patients with a gastro-esophageal junction tumor with positive cervical lymph nodes had no positive lymph nodes in the chest. One of them only had involvement of lymph nodes in the vicinity of the tumor, another one only had positive lymph nodes in the vicinity of the tumor and in the hepato duodenal ligament. Consequently those three patients changed from stage 3 to stage 4 disease.
The consequence of these findings is evident. Diagnosis of positive lymph nodes in the neck by clinical staging remains problematic because of the shortcoming of ultrasound, CAT scan and EUS in this particular region [8]. Adding a PET scan to the preoperative work-up probably will improve the detection of positive lymph nodes and could have a major impact on diagnosis and treatment. Although PET scan seems promising, taking into account the very accurate diagnosis of mediastinal nodal involvement in non-small-cell lung cancer [17], we cannot make any conclusion for the reason why this investigation was not performed systematically in all patients. Further prospective study is currently been carried out.
The finding of positive cervical lymph nodes in a substantial fraction of advanced tumor stage questions the interpretation of the accuracy of induction therapy modalities. Furthermore when using chemoradiotherapy as an induction therapy modality the question arises whether to include the entire mediastinum but also the supraclavicular area and the neck in the field of irradiation. Needless to stress that enlarging the area to irradiate to such an extent will increase morbidity and possibly mortality.
The finding of unforeseen positive lymph nodes in the neck and especially in the absence of thoracic lymph node metastasis in the distal third and gastro-esophageal adenocarcinoma raises the question about the value of extensive lymphadenectomy in particular the three-field lymphadenectomy in relation to prolonged tumor-free survival and improvement of cure rate [9]. In this study we only analyzed the pattern of lymph node metastasis, we did not look at survival and recurrence rates firstly because the group we selected was very small and secondly because 5-year survival is not reached yet. Within due course, results will become available.
Over recent years there is overwhelming evidence that R0 dissection (no residual tumor left behind) is the most important prognostic variable after surgery. To achieve R0 resection, organ dissection and lymphadenectomy must be radical. It has to be emphasized that local disease free survival is an important goal to achieve in carcinoma of the esophagus and gastro-esophageal junction, the majority of patients presenting themselves with advanced stage at the time of diagnosis. Clark et al. [10] analyzed in detail the operative specimen for 43 patients undergoing a transthoracic en bloc esophagectomy for adenocarcinoma of the esophagus and the cardia in relation to the pattern of recurrence at follow-up. They found that nodal recurrence occurred only in 8% within the area of dissection. This low percentage of local recurrence is in sharp contrast to the rate of local recurrence after transmediastinal blunt dissection of the esophagus.
Barbier et al. [11] found local recurrence in more than 50% of cases after standard esophagectomy, i.e. after incomplete lymphadenectomy. Whether adding the cervical field to the lymphadenectomy will be beneficial in the prophylaxis of recurrence for adenocarcinoma of the distal third and gastro-esophageal junction is a question that cannot be answered at this moment and still awaits confirmation.
The most important question to be answered of course is whether more radical dissection really contributes to improvement of survival.
Hagen et al. [12] performed a prospective randomized trial on 69 patients comparing extended en bloc resection versus transhiatal standard esophagectomy for carcinoma of the lower esophagus and cardia and showed a 5-year survival being significantly better after en bloc resection: 41% versus 21% for transhiatal resection. This study is lacking sufficient power as only 69 patients were involved and as patient material both included squamous cell carcinoma and adenocarcinoma of the distal third of the esophagus. Kato et al. [16] compared two-field versus three-field lymphadenectomy. The differences in 5-year survival were 48.7% in three-field lymphadenectomy versus 33.7% in two-field lymphadenectomy. The major critic on this study however was the difference in patient characteristics.
Similarities between the pattern of lymph node spread in adenocarcinoma of the distal esophagus and the GEJ, especially in relation to the findings in the cervical field, raises the question about the oncological behavior of these tumors, the actual TNM classification of adenocarcinomas of the distal third and tumors of the gastro-esophageal junction and consequences related to surgical strategies.
The UICC suggests classifying adenocarcinoma involving more then 50% of the esophagus as esophageal carcinoma and those involving more then 50% of the stomach including those equally distributed as gastric carcinoma. In our opinion this UICC TNM classification ignores one of the essential questions: carcinoma of the esophago-gastric junction, because of its particular anatomical location, behaves differently from carcinoma of the esophagus or stomach. Recent data from the literature showed Barrett metaplasia as the source of adenocarcinoma of the cardia in up to 50% of adenocarcinomas of the Gastro-esophageal junction. This data suggests a common origin of adenocarcinoma of the esophagus and adenocarcinoma at the GEJ and a behavior similar to that of esophageal carcinoma [3,9]. Further evidence on Japanese study and some western studies suggest that carcinoma of the esophagus and the GEJ largely share patterns of age distribution sex distribution and morphological characteristics [2,13]. When compared with infracardiac gastric carcinoma, there seems to be highly significant differences in age distribution and micro and macroscopic appearances between gastro-esophageal junction tumors and gastric carcinoma. These differences suggest that GEJ tumors are more closely related to the esophagus than to the stomach. The data from previous literature and from the present experience seem to support the thesis that gastro-esophageal carcinomas should be classified as esophageal carcinomas in the TNM classification. These findings question the value of the actual TNM staging for carcinoma of the GEJ especially in relation to lymph node status. In the actual TNM classification tumors of the GEJ are classified as gastric carcinomas and therefore the finding of positive lymph nodes in the chest equals stage 4 disease which means incurable disease. However from our own earlier published experience with 95 resections for GEJ tumors [14], 5-year survival of 11% was obtained in stage 4 disease. Analyzing the survival with both abdominal and thoracic involvement of lymph nodes showed a 5-year survival of 13%. These survival figures are very much similar to the 15% 5-year survival obtained in patients with carcinoma of the thoracic esophagus with positive lymph nodes [6]. The consequence of these findings in view of the frequent involvement of thoracic lymph nodes in up to 40% in tumors of the GEJ are clear. Lymph node dissection of the posterior mediastinum up to the carina is necessary to obtain a correct pathological staging. This favors a transthoracic approach, which will always result in a better and more complete removal of mediastinal lymph nodes then any other approach [15]. Furthermore the detection of disease of intrathoracic lymph nodes by different staging methods, either non-invasive (endoscopic ultrasonography) or invasive (thoracoscopy), should not exclude patients from treatment modalities with curative intent in particular surgery. For these reasons we suggest that diseased intrathoracic lymph nodes should no longer be considered as incurable stage 4 disease; we suggest rather that GEJ tumors should be classified as esophageal carcinomas and staged accordingly, i.e. positive intra-thoracic lymph nodes as stage 3 disease.
| Footnotes |
|---|
| Appendix A. Conference discussion |
|---|
|
|
|---|
Dr De Leyn: First of all, how do we stage these patients? We follow the international classification. So in our department, gastroesophageal junction tumors are still staged according to gastric cancer staging. Regarding survival, this is indeed a very difficult question. And there are some articles from Professor Skinner's group which show that in stage III disease, and mainly in stage III disease, there seems to be a better survival: 30% for patients with radical en bloc dissection, part of them had three-field lymphadenectomy: versus 11 or 12%. The question is, of course, is this not a better selection of stage III patients? I mean, if you do a two-field lymphadenectomy and you find stage III disease, it is possible that with bilateral it would have been stage IV. So are the better results of three-field lymphadenectomy not just a better staging (with stage migration) of patients? It is very difficult to answer. We did not attempt to answer this question, and I don't know if there is an effect on survival.
On the question of morbidity: this is also a very important question, because it's important, of course, to look at morbidity because that surgery is more demanding. It depends on the experience, but it takes 22.5 h more. Maybe I can show you one discussion slide. (Slide) In an earlier experience we have looked at about 40 patients with three-field lymphadenectomy and looked at the morbidity. We had no mortality in this group. Pulmonary complications were found in about one-third of the patients, but this is very comparable to our overall problem with pulmonary complications. Recurrent nerve palsy was seen in two patients. But in this group we didn't find a higher morbidity. For the local regional recurrence: when you look at the literature, again Altorki and other groups, who are doing radical surgery, the local regional recurrence will be somewhere around 10%. In our experience it was 17%.
Dr Ellis: May I make one last comment on the question of staging esophageal cancers. The new classification of the AJCC, which is supposedly the same as that of the UICC, now stages tumors of the lower esophagus with celiac node involvement as M1a which places them in Stage IV. Both Professor Lerut and I agree that this is probably not appropriate. Furthermore, the new staging criteria don't take into account the number of nodes involved which both Dr Skinner and others, including ourselves, think is essential for proper staging of these tumors. While perhaps this isn't the best venue for discussing staging criteria, I would like to make a plea to all of us involved in this field to be sure that the next published esophageal cancer staging criteria include some of these suggestions, since, in the opinion of many of us, the new 1997 AJCC staging criteria is suboptimal.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. P. Barbour, N. P. Rizk, M. Gonen, L. Tang, M. S. Bains, V. W. Rusch, D. G. Coit, and M. F. Brennan Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome Ann. Surg. Oncol., February 1, 2007; 14(2): 306 - 316. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ueda, A. Shiozaki, H. Itoi, K. Okamoto, H. Fujiwara, D. Ichikawa, S. Kikuchi, N. Fuji, T. Itoh, T. Ochiai, et al. The Range of Tumor Extension Should Have Precedence over the Location of the Deepest Tumor Center in Determining the Regional Lymph Node Grouping for Widely Extending Esophageal Carcinomas Jpn. J. Clin. Oncol., December 1, 2006; 36(12): 775 - 782. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Lagarde, F. J.W. ten Kate, J. B. Reitsma, O. R.C. Busch, and J. J. B. van Lanschot Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction J. Clin. Oncol., September 10, 2006; 24(26): 4347 - 4355. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Igaki, H. Kato, Y. Tachimori, H. Sato, H. Daiko, and Y. Nakanishi Prognostic evaluation for squamous cell carcinomas of the lower thoracic esophagus treated with three-field lymph node dissection Eur. J. Cardiothorac. Surg., June 1, 2001; 19(6): 887 - 893. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Hosch, N. H. Stoecklein, U. Pichlmeier, A. Rehders, P. Scheunemann, A. Niendorf, W. T. Knoefel, and J. R. Izbicki Esophageal Cancer: The Mode of Lymphatic Tumor Cell Spread and Its Prognostic Significance J. Clin. Oncol., April 1, 2001; 19(7): 1970 - 1975. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |